Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
Nvision Laser Eye Centers · Dry Eye · Asthenopia
Not applicable
Completed
103
2024-06
Industry sponsor intelligence
Nvision Laser Eye CentersClinical Pipeline.
Lead-sponsor view of Nvision Laser Eye Centers's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 0
Pipeline overview
Programs by phase and activity.
Velocity
Nvision Laser Eye Centers trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Calcitonin → | 1 | 0 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Nvision Laser Eye Centers studies.
This page groups studies where Nvision Laser Eye Centers is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates